Hector Wiltz Jr, MD
Dermatology · Miami, FLNPI 1851404479
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 267 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,243 and has fallen 52.2% since, to $594 in 2025.
Across 267 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$805
- LEO Pharma Inc.$628
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$579
- Regeneron Healthcare Solutions, Inc.$552
- Amgen$496
- Pfizer$367
- plus $2K from 28 others
Across 578 payments — averaging $11,002 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Taro Pharmaceuticals USA, Inc.$3.1M
- Takeda Pharmaceuticals U.S.A., Inc.$961K
- Sun Pharmaceutical Industries Inc.$882K
- Teva Pharmaceuticals USA, Inc.$508K
- Pfizer$318K
- Dr.reddy's Laboratories,inc.$185K
- plus $385K from 4 others
What the payments were for
- Food & beverage$5,403100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 31 | $805 |
| LEO Pharma Inc. | 30 | $628 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 30 | $579 |
| Regeneron Healthcare Solutions, Inc. | 21 | $552 |
| Amgen | 22 | $496 |
| Pfizer | 26 | $367 |
| Genentech USA, Inc. | 17 | $318 |
| Journey Medical Corporation | 18 | $212 |
| Incyte Corporation | 7 | $151 |
| Galderma Laboratories, L.p. | 7 | $146 |
| Johnson & Johnson | 6 | $122 |
| AbbVie(2 entities) | 5 | $112 |
| VYNE Pharmaceuticals Inc. | 5 | $104 |
| Sandoz | 4 | $82 |
| Bristol Myers Squibb | 4 | $81 |
| Sun Pharmaceutical Industries Inc. | 4 | $73 |
| E.r. Squibb & Sons, L.L.C. | 3 | $69 |
| Almirall LLC | 3 | $67 |
| Mayne Pharma Commercial LLC | 5 | $63 |
| Arcutis Biotherapeutics, Inc. | 2 | $48 |
| Revance Therapeutics, Inc. | 1 | $39 |
| Dermavant Sciences, Inc. | 2 | $39 |
| Promius Pharma LLC | 2 | $35 |
| Novartis | 1 | $31 |
| Strata Skin Sciences, Inc. | 2 | $25 |
| Aclaris Therapeutics, Inc. | 1 | $25 |
| Genentech, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $24 |
| EPI Health, LLC | 1 | $20 |
| Organogenesis Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $15 |
| Sebela Pharmaceuticals Inc. | 1 | $13 |
| Organon | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,403 in reported general payments places this provider in the 65th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 31 | $152,908 |
| Dupixent PenDupilumab | 14 | $52,314 |
| Ammonium Lactate | 823 | $21,319 |
| Mometasone Furoate | 1,063 | $19,442 |
| Fluorouracil | 192 | $15,964 |
| Ciclopirox | 379 | $13,340 |
| Calcipotriene-BetamethasoneCalcipotriene/Betamethasone | 13 | $13,086 |
| Ketoconazole | 973 | $12,486 |
| Calcipotriene | 63 | $12,294 |
| Triamcinolone Acetonide | 999 | $8,177 |
| Metronidazole | 128 | $7,604 |
| Hydrocortisone | 753 | $3,953 |
| Clindamycin Phosphate | 118 | $3,061 |
| Betamethasone Dipropionate | 65 | $2,639 |
| Azelaic Acid | 24 | $2,580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $496 | $152,90831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,147 dermatology providers in Florida.
Other dermatology in Miami
- Francisco KerdelMiami$2.1M
- Robert KirsnerMiami$1.4M
- Gil YosipovitchMiami$1M
- Mercedes GonzalezMiami$943K
- Heather Woolery LloydMiami$609K
- Hadar Lev-TovMiami$326K
- Lawrence SchachnerMiami$309K
- Giovanna CioccaMiami$222K
- Janice Lima MaribonaMiami$217K
- Jill WaibelMiami$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.